Niopam 200 solution for injection 20ml vials

Ország: Egyesült Királyság

Nyelv: angol

Forrás: MHRA (Medicines & Healthcare Products Regulatory Agency)

Aktív összetevők:

Iopamidol

Beszerezhető a:

Bracco UK Ltd

INN (nemzetközi neve):

Iopamidol

Adagolás:

200mg/1ml

Gyógyszerészeti forma:

Solution for injection

Az alkalmazás módja:

Intraventricular cardiac; Intraarterial; Intraarticular; Intravenous

Osztály:

No Controlled Drug Status

Recept típusa:

Valid as a prescribable product

Termék összefoglaló:

BNF: ; GTIN: 5013837312111

Termékjellemzők

OBJECT 1
NIOPAM 200
Summary of Product Characteristics Updated 26-Jul-2016 | Bracco UK
Limited
1. Name of the medicinal product
NIOPAM 200, solution for injection.
2. Qualitative and quantitative composition
40.8 % w/v Iopamidol equivalent to 200mg iodine/ml. Each ml contains
408.2 mg Iopamidol. For the full
list of excipients, see 6.1.
3. Pharmaceutical form
Solution for injection.
Clear aqueous solution filled into colourless glass ampoules or
bottles.
4. Clinical particulars
4.1 Therapeutic indications
This medicinal product is for diagnostic use only.
X-ray contrast medium for use in lumbar and thoraco-cervical
myelography, computer tomography
enhancement.
4.2 Posology and method of administration
Route of administration
Intra-ventricular
Intra-venous Intra-thecal Intra-cisternal
PosologyNIOPAM 200: DOSAGE SCHEDULE
Procedure
Dosage
Lumbar Myelography
Adults
10 - 15 ml
Thoracc-Cervical Myelography
Adults
5 - 15 ml
Computer Tomography Enhancement
Adults: Brain scanning
Whole body scanning
50 - 100ml
40-100ml
The dosage must be adapted to the examination, the age, body weight,
cardiac output, renal function,
general condition of the patient and the technique used. Usually the
same iodine concentration and
volume are used with other iodinated x-ray contrast in current use.
As with all contrast media, the lowest dose necessary to obtain
adequate visualisation should be used.
Method of administration
Non-ionic contrast media have less anti-coagulant activity _in-vitro
_than ionic media. Meticulous attention
should therefore be paid to angiographic technique. Non-ionic media
should not be allowed to remain in
contact with blood in the syringe and intravascular catheters should
be flushed frequently, to minimise the
risk of clotting, which rarely has led to serious thromboembolic
complications after procedures. Factors
such as length of procedure, catheter and syringe material, underlying
disease state, and concomitant
medications may contribute to the development of thromboembolic
events. Therefore, meticulous
angio